ReviewInternational journal of molecular sciences2021
Utilization of Pharmacological Ascorbate to Enhance Hydrogen Peroxide-Mediated Radiosensitivity in Cancer Therapy.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Two-color spheroid model for determining the OJournal of biological engineering · 2026Article
- Gallium disrupts endoplasmic reticulum iron metabolism to induce lipid metabolic reprogramming in glioblastoma cells.iScience · 2025Article
- Glutathione peroxidase 4 overexpression induces anomalous subdiffusion and impairs glioblastoma cell growth.Journal of biological engineering · 2024Article
- Gallium Uncouples Iron Metabolism to Enhance Glioblastoma Radiosensitivity.International journal of molecular sciences · 2024Article
- Review of the Potential Role of Ascorbate in the Prevention and Treatment of Gynecological Cancers.Antioxidants (Basel, Switzerland) · 2024Review
- Nanoparticle-Based Antioxidants in Stress Signaling and Programmed Cell Death in Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2023Review
- Ionizing Radiation, Antioxidant Response and Oxidative Damage: Radiomodulators.Antioxidants (Basel, Switzerland) · 2023Article
- Manipulation of Redox Metabolism Using Pharmacologic Ascorbate Opens a Therapeutic Window for Radio-Sensitization by ATM Inhibitors in Colorectal Cancer.International journal of radiation oncology, biology, physics · 2023Article
- Fucoidan/UVC Combined Treatment Exerts Preferential Antiproliferation in Oral Cancer Cells but Not Normal Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy.Frontiers in immunology · 2022Review
- Ascorbate Preferentially Stimulates Gallium-67 Uptake in Glioblastoma Cells.Journal of nuclear medicine & radiation therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Interest in the use of pharmacological ascorbate as a treatment for cancer has increased considerably since it was introduced by Cameron and Pauling in the 1970s. Recently, pharmacological ascorbate has been used in preclinical and early-phase clinical trials as a selective radiation sensitizer in cancer. The results of these studies are promising. This review summarizes data on pharmacological ascorbate (1) as a safe and efficacious adjuvant to cancer therapy; (2) as a selective radiosensitizer of cancer via a mechanism involving hydrogen peroxide; and (3) as a radioprotector in normal tissues. Additionally, we present new data demonstrating the ability of pharmacological ascorbate to enhance radiation-induced DNA damage in glioblastoma cells, facilitating cancer cell death. We propose that pharmacological ascorbate may be a general radiosensitizer in cancer therapy and simultaneously a radioprotector of normal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.